Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.21), versus ($0.28) reported last year. Revenue for the quarter came in at $95.5 million, versus $37.5 million reported last year.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.